- Home
- NRXS vs SYBX Comparison
NRXS vs SYBX Comparison
Compare NRXS & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- SYBX
- Stock Information
- Founded
- NRXS 2011
- SYBX N/A
- Country
- NRXS United States
- SYBX United States
- Employees
- NRXS N/A
- SYBX N/A
- Industry
- NRXS
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- SYBX Health Care
- Exchange
- NRXS Nasdaq
- SYBX Nasdaq
- Market Cap
- NRXS 13.0M
- SYBX 13.6M
- IPO Year
- NRXS 2023
- SYBX N/A
- Fundamental
- Price
- NRXS $2.49
- SYBX $1.26
- Analyst Decision
- NRXS Strong Buy
- SYBX
- Analyst Count
- NRXS 1
- SYBX 0
- Target Price
- NRXS $7.00
- SYBX N/A
- AVG Volume (30 Days)
- NRXS 155.9K
- SYBX 7.8K
- Earning Date
- NRXS 08-08-2025
- SYBX 08-07-2025
- Dividend Yield
- NRXS N/A
- SYBX N/A
- EPS Growth
- NRXS N/A
- SYBX N/A
- EPS
- NRXS N/A
- SYBX 0.21
- Revenue
- NRXS $2,934,945.00
- SYBX N/A
- Revenue This Year
- NRXS $138,883.78
- SYBX N/A
- Revenue Next Year
- NRXS $118.59
- SYBX N/A
- P/E Ratio
- NRXS N/A
- SYBX $5.82
- Revenue Growth
- NRXS 27.52
- SYBX N/A
- 52 Week Low
- NRXS $1.33
- SYBX $0.90
- 52 Week High
- NRXS $6.20
- SYBX $1.88
- Technical
- Relative Strength Index (RSI)
- NRXS 49.91
- SYBX 52.81
- Support Level
- NRXS $2.33
- SYBX $1.17
- Resistance Level
- NRXS $2.67
- SYBX $1.27
- Average True Range (ATR)
- NRXS 0.17
- SYBX 0.04
- MACD
- NRXS -0.01
- SYBX -0.01
- Stochastic Oscillator
- NRXS 46.43
- SYBX 40.00
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.